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Abstract
Dengue virus (DENV) is the etiologic agent for dengue fever, for which there is no approved vaccine or specific anti-viral
drug. As a remedy for this, we explored the use of compounds that interfere with the action of required host factors and
describe here the characterization of a kinase inhibitor (SFV785), which has selective effects on NTRK1 and MAPKAPK5
kinase activity, and anti-viral activity on Hepatitis C, DENV and yellow fever viruses. SFV785 inhibited DENV propagation
without inhibiting DENV RNA synthesis or translation. The compound did not cause any changes in the cellular distribution
of non-structural 3, a protein critical for DENV RNA synthesis, but altered the distribution of the structural envelope protein
from a reticulate network to enlarged discrete vesicles, which altered the co-localization with the DENV replication complex.
Ultrastructural electron microscopy analyses of DENV-infected SFV785-treated cells showed the presence of viral particles
that were distinctly different from viable enveloped virions within enlarged ER cisternae. These viral particles were devoid of
the dense nucleocapsid. The secretion of the viral particles was not inhibited by SFV785, however a reduction in the amount
of secreted infectious virions, DENV RNA and capsid were observed. Collectively, these observations suggest that SFV785
inhibited the recruitment and assembly of the nucleocapsid in specific ER compartments during the DENV assembly process
and hence the production of infectious DENV. SFV785 and derivative compounds could be useful biochemical probes to
explore the DENV lifecycle and could also represent a new class of anti-virals.
Citation: Anwar A, Hosoya T, Leong KM, Onogi H, Okuno Y, et al. (2011) The Kinase Inhibitor SFV785 Dislocates Dengue Virus Envelope Protein from the
Replication Complex and Blocks Virus Assembly. PLoS ONE 6(8): e23246. doi:10.1371/journal.pone.0023246
Editor: Andrew Pekosz, Johns Hopkins University - Bloomberg School of Public Health, United States of America
Received April 27, 2011; Accepted July 11, 2011; Published August 17, 2011
Copyright:  2011 Anwar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Agency for Science, Technology and Research of Singapore and the Singapore Ministry of Health Awards R-913-200-
002-304 (to M.G.B), and by Grants-in-aid (MH) from Japan Science and Technology Agency, the Ministry of Education, Culture, Sports, Science, and Technology of
Japan (21249013), The Uehara Memorial Foundation, The Naito Foundation Natural Science Scholarship, and Takeda Science Foundation (to M. H.). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Some of the authors have an ownership stake in the company KinoPharma. This does not alter the authors’ adherence to all the PLoS
ONE policies on sharing data and materials.
* E-mail: gmsaa@nus.edu.sg (AA); hagiwara.masatoshi.8c@kyoto-u.ac.jp (MH); mariano.garciablanco@duke-nus.edu.sg (MAG-B)
Introduction
Dengue fever, the most prevalent arthropod-borne viral diseases
of humans [1], can be caused by four DENV serotypes (DENV-1,
DENV-2,DENV-3,and DENV-4).DENV belongstotheFlaviviridae
family, which comprises other medically important pathogens
including the Japanese encephalitis (JEV), yellow fever (YFV) and
hepatitis C (HCV) viruses [2]. There is no available effective anti-
viral therapy for DENV infection and the development of a dengue
vaccine is challenging because of the need to induce long-lasting
protection against all four DENV serotypes simultaneously. In fact,
infection with one DENV serotype does not produce lasting
immunity against the other three, and during secondary infections,
incomplete immunity against a new serotype can increase the
likelihood of life-threatening dengue hemorrhagic fever (DHF) or
dengue shock syndrome (DSS) [3]. With approximately 3.6 billion
people at risk, the global distribution of all serotypes [4], and the
complications inherent in vaccine development, it is essential to
obtain effective therapies against DENV infection.
The DENV replication cycle begins with receptor-mediated
endocytosis of the virus into cells, followed by fusion with the
endosomal membrane to release the viral genome into the
cytoplasm for translation and replication [2]. Replication of the
viral RNA genome takes place within virus-induced endoplasmic
reticulum (ER)-like vesicles, which are connected to the cytosol via
pores that allow entry of factors that are required for RNA
synthesis, and exit of newly synthesized viral RNA for assembly.
Virus assembly occurs within ER vesicles that are in close
proximity to these pores, with the ensuing accumulation of these
viruses in dilated ER compartments proximal to the Golgi. All
these processes occur within compartments of one ER-derived
network [5,6]. Virions are subsequently released from cells via the
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replication require complex interaction between viral and cellular
factors [7,8]. Hence, small molecules that target critical host
factors could be useful for the biochemical characterization of
host–virus interactions and are anti-DENV drug candidates.
In this study we describe the anti-viral activity of SFV785, a
derivative of SRPIN340, a serine-arginine-rich protein kinase
(SRPK) inhibitor [9]. Here we show that SFV785 inhibited the
replication of HCV, and had potent anti-DENV and anti-YFV
activity. While SFV785 did not inhibit the accumulation of DENV
proteins and RNAs, it altered the distribution of the structural
envelope (Env) protein within ER-derived vesicles, which was
consistent with the altered morphology of the ER network it
caused in uninfected cells. Ultrastructural electron microscopic
analyses of DENV-infected SFV785-treated cells showed the
presence of virion-like particles devoid of the dense nucleocapsid
and thus distinctly different from viruses within enlarged ER
cisternae. SFV785 did not inhibit the secretion of the virion-like
particles, but inhibited the production of infectious virus. These
data indicate that SFV785 inhibited the recruitment and
encapsulation of the nucleocapsid in specific ER compartments
during the DENV assembly process.
Materials and Methods
This study was carried out in strict accordance with the
recommendations in the Guidelines for Proper Conduct of Animal
Experiments (Ministry of Education, Culture, Sports, Science, and
Technology of Japan), and approved by the Tokyo Medical and
Dental University (Approval number 100185).
Cell lines and viruses
The dengue virus 2 New Guinea C strain (DENV-2) and yellow
fever 17D strain (YFV) used in this study were propagated in the
C6/36 (ATCC) and Vero (ATCC) cells respectively as described
[10]. Baby hamster kidney (BHK-21; ATCC) and Vero cells were
used for the quantification of DENV and YFV by plaque assay
respectively. In brief, cells were grown in 24 well plates and
infected the next day with the virus. The cells were processed for
plaque forming unit (PFU) determination 6 days (DENV) or 3 days
(YFV) post-infection. All statistical analyses were carried out with
GraphPad Prism 4 (GraphPad Software). For the infection of
control and siRNA-treated HuH-7 cells, DENV was used at a
multiplicity of infection (MOI) of 1. The cells were incubated
with the virus for 1 hr at 37uC with occasional rocking. After 1 hr,
the cells were rinsed, overlaid with complete medium and
incubated for 36 hours post-infection. For drug-treated cells,
the compounds were added to the complete media after the
1 hr virus adsorption step, and incubated for the indicated
amount of time. HuH-7/Rep-Feo [11] cells were maintained
in DMEM and 200 mg/ml G418. HuH-7.5.1 cells [12] were
maintained in DMEM supplemented with 10% fetal calf serum.
The hepatitis C virus (HCV)-JFH1 was obtained from HuH-7.5-1
cells as described [13].
Kinase screen and anti-kinase activity
All kinases were assayed at an inhibitor concentration of 10 mM
and an ATP concentration of 10 mM, unless otherwise stated.
Radioisotope-based assays were performed for NTRK1, SRPK1,
SRPK2, CLK4 and DYRK1A as previously described [9]. The
inhibition on 66 kinases was assessed by Carna Biosciences
Quickscout
TMCustomProfilingServiceusingthephosphor-peptide
ELISA assays, IMAP assays and Off-chip Mobility Shift Assays
(MSA). The detailed assay protocols for these kinases and assays are
available from the Millipore website (http://www.carnabio.com/
output/pdf/ProfilingProfilingBook_en.pdf). The inhibitory effect
on the other kinases was examined with the Millipore Kinase
Profiler
TM Service using radioisotope-based assays. A detailed
assay protocol is available from Millipore website (http://www.
millipore.com/publications.nsf/a73664f9f981af8c852569b9005b4eee/
5b63719614ecf1aa85257367000523ee/$FILE/cd1000enus.pdf).
Evaluation of the effect of the compounds on the
replication of a HCV subreplicon
We synthesized ten derivative compounds (see Supporting
Information S1) based on the chemical structure of SRPIN340 [9].
All tested compounds were dissolved in 100% DMSO, and were
diluted with 100% DMSO, if necessary. Evaluation of the
inhibitory effect of the compounds on the replication of HCV
sub-replicon was performed as reported previously [11]. The Rep-
Feo subreplicon consists of the 59UTR of the HCV-N, the fusion
gene of neomycin phosphotransferase (Neo) with the firefly
luciferase (Fluc), the EMCV IRES driving translation of the NS3
to NS5B genes of HCV-N, and the 39UTR of HCV-N. In brief,
HuH-7/Rep-Feo cells were plated onto 96-well plates at 5610
3
cells/well 16 to 24 hrs prior to the addition of the compounds.
Each compound was added at a final concentration of 10 or
20 mM in the presence of 0.04% DMSO, and incubated for an
additional 48 hours. After incubation, cells were lysed with the Glo
lysis buffer (Promega) and the luciferase activity measured by
Bright-Glo
TM Luciferase Assay System (Promega) on the ARVO
MX multilabel counter (PerkinElmer Life Sciences). The lumi-
nescence intensity of each sample was reported relative to that of
the well treated with 0.04% DMSO (100% luciferase activity).
siRNA transfection procedures and analyses of gene
expression
The C2 siRNA (non-specific siRNA duplex) used has been
previously reported [14]. C2 and NTRK1-specific siRNAs (TrkA-
3) were synthesized from Sigma, and TrkA-12 siRNA was
obtained from Thermo Scientific (Table S1). siRNA transfections
were performed on HuH-7 cells with using Lipofectamine 2000 as
described [15]. At 78 h post-transfection, cells were plated at a
density of 3610
5 cells per 35 mm well, and infected the day after
with DENV-2 at an MOI of 1. The supernatant were harvested
36 hrs p.i., and the cells collected for plaque, western and
quantitative real time PCR analyses. For Western blot analysis,
harvested cells lysates were resolved on a 10% SDS-PAGE,
transferred onto a nitrocellulose membrane and the appropriate
proteins detected by labeling using a polyclonal anti-NTRK1
(Millipore) or anti-GAPDH (Cell Signaling Technology) antibod-
ies. The levels of proteins were quantified using Quantity One
(Bio-Rad).
DENV-2 replicon, RNA transfection and luciferase assay
The RNA from the pDRrep DENV-2 plasmid replicon [16]
was prepared as described. The replicon is shown to be able to
translate and replicate similar to wild type DENV RNA,
generating two peaks of luciferase activities indicative of
translation from input (within first 8 hrs) and newly synthesized
(48 hrs post-transfection) RNA. Briefly, the DENV-2 replicon
RNA was generated from linearised pDRep by in vitro transcrip-
tion using the RiboMax Large Scale RNA Production System
(Promega). The replicon transcripts were transfected into HuH-7
cells by electroporation together with a transfection control firefly
luciferase mRNA, obtained from in vitro transcription of a
linearized pTNT-Fluc plasmid containing the firefly gene in the
Kinase Inhibitor to Dengue Virus Assembly
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23246pTNT vector (Promega). The electroporated cells were first pooled
and then aliquoted into 24-well plates. Luciferase activity, which is
an indication of translation from the replicon, was measured 2 to
72 hrs post-transfection to assess for the effects of the drugs on
DENV replicon activity. The analyses of both firefly and Renilla
luciferase levels were performed using the dual-luciferase assay kit
(Promega) on a Tecan Infinite M200 luminometer.
RT-PCR and quantitative real-time PCR
Total RNA was prepared from infected cells using the
TRIzolHReagent (Invitrogen) according to manufacturer’s instruc-
tions. The RT reaction was performed at 42uC as described [17].
All quantitative real-time PCR was performed on the iCycler
iQ
TM Multi-Color Real Time PCR Detection System (Bio-Rad)
with the following conditions: 40 cycles of 30 s denaturation at
95uC, 30 s annealing at 55uC and 30 s extension at 72uC.
Fluorescent detection of SYBR Green I (iQ SYBR Green
Supermix, Bio-Rad) was carried out at the extension phase. All
cDNA standards used in quantitative real-time PCR were identical
in size and sequence to the targets and were generated by PCR
using Taq polymerase (Promega) and 50 nM of each primer, with
the following cycling conditions: a 95uC step for 3 min; 25 cycles
of 95uC for 30 s, 55uC for 30 s, and 72uC for 1 min; and an
elongation step at 72uC for 7 min. The quantification of viral and
cellular nucleic acids in cell culture studies was normalized against
the expression levels of actin. The sequences of the primers used
are shown in Table S1. All statistical analyses were carried out
with GraphPad Prism 4.
Immunofluorescence
DENV-2 infected HuH-7 cells or HCV JFH-1 infected HuH
7.5-1 cells were fixed with 4% paraformaldehyde or ice-cold
methanol, and processed for indirect immunoflourescence as
described [15]. The proteins were labelled with anti-NS3 rabbit
polyclonal (Abcam or from Dr. Padmanabhan, Georgetown
University), anti-DENV-2 Env 3H5 mouse monoclonal (Chemi-
con), anti-calnexin rabbit monoclonal (Cell Signalling), anti-sec31
(gift from Dr. Tang B.L., NUS), anti-ERGIC-53 (Sigma-Aldrich)
and anti-Giantin (Abcam) rabbit polyclonals, and visualized using
secondary antibodies conjugated to FITC, rhodamine (Jackson
Immunolabs) or Cy3 (Amersham). The double-stranded RNA
(dsRNA), the presumed intermediate of DENV replication, was
labeled with J2, a mouse monoclonal antibody (English and
Scientific Consulting, Hungary). Cellular DNA was visualised with
DAPI (Molecular Probes). Images were collected using a
fluorescence microscope (Olympus IX700). For the quantification
Figure 1. Structure-activity relationship of SRPIN340/nicotinoyl derivatives to the replication of the HCV subreplicon. The
comparison of the relative luciferase activity (luc activity) and viability (viability) with the solvent (0.04% DMSO) in the presence of 10 or 20 mM of the
compounds are shown. L/V is the ratio of relative luciferase activity to viability. L/V values less than 50 (20 mM) or 60 (10 mM) are highlighted. The data
are represented as the mean of triplicate experiments.
doi:10.1371/journal.pone.0023246.g001
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immunostained cells were analyzed using an ArrayScan VTi.
Infected cell number was defined as the number of nuclei which
average signal intensity of Cy3 signal around nuclei was greater
than the mean +4 S.D. of that from uninfected cells.
Results
Synthesis and characterization of SFV785, a kinase
inhibitor that inhibits HCV replication
SRPK inhibitor, SRPIN340, has been reported to have anti-
viral activity against several RNA viruses including HIV, Sindbis
virus, and HCV [9,18]. In an attempt to optimize the anti-HCV
reactivity of this inhibitor, we synthesized ten new (iso)nicotinoyl
derivatives of SRPIN340 and tested them for their effects on the
replication of a HCV subreplicon, Rep-Feo [11], which codes for
luciferase (Figure 1). The level of luciferase activity has been
previously reported to correlate with amount of HCV subreplicon
RNA produced, and hence serves as a useful tool for the
quantitative evaluation of the effects of compounds on HCV
replication. Among the ten SRPIN340 derivatives, 1-[2-(1-
azacyclooctanyl)- 5-(trifluoromethyl)] phenyl-3-nicotinoylthiourea,
designated as SRPIN785 [now renamed as suppressor of
flaviviridae-785 (SFV785)], had the most potent inhibitory effect
on the replication of Rep-Feo (cells treated with 20 mM SFV785
had luciferase activity that was 39% of control).
We investigated the possibility that SFV785 could also inhibit
the replication of HCV virus, JFH1. The percentage of cells
infected with JFH1 at 48 hrs post-infection (p.i.) was significantly
reduced in the presence 10 mM SFV785, as compared to vehicle
Figure 2. SFV785 inhibits HCV replication. (A) Detection of HCV JFH1-infected cells. HuH 7.5-1 cells were infected with HCV JFH1 and treated
with the compounds SFV785 or SRPIN614 for 48 hours. The cells were fixed and immunostained with an anti-HCV NS3 antibody. (B) Quantitative
analysis of HCV JFH1-infected cells. HuH-7.5-1 cells were seeded in 96 well plates, infected with HCV JFH1 and treated with the compounds SFV785 or
SRPIN614 as described above. The fixed cells were immunostained with an anti-HCV NS3 mouse monoclonal antibody, and the percentage of NS3-
positive cells measured using the ArrayScan VTi. The bars indicate the mean value 6 S.D. from triplicate experiments.
doi:10.1371/journal.pone.0023246.g002
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Figure 1). Quantitative analysis of NS3 expression showed that
about 7% of the cells were infected in the presence 10 mM
SFV785, whereas about 60% of the cells were infected in the
presence of SRPIN614, or vehicle (0.1% DMSO) (Figure 2B).
Hence SFV785 also inhibited the replication of the intact HCV
JFH1 virus, possibly more efficiently than the replication of the
HCV Rep-Feo subreplicon.
The parent compound of SFV785, SRPIN340, is an inhibitor of
the SR protein kinases SRPK1 and SRKP2 [18]. In order to
determine if SFV785 retained its kinase inhibitory activity and
specificity for SRPK, we screened the effect of this compound on
the kinase activity of a library of 295 kinases in vitro. Kinases that
showed a reduction in activity of more than 50% were considered
to be potential targets for SFV785. Out of the 295 screened,
SFV785 inhibited the activities of the tropomyosin receptor kinase,
TrkA (NTRK1) and PRAK (MAPK-activated protein kinase 5;
MAPKAPK5) to 27% and 48% respectively (Table S2), suggesting
that these proteins were targets of SFV785.
SFV785 is a potent inhibitor of DENV
Given the evolutionary proximity of HCV and flaviviruses, and
the fact that several kinase inhibitors have been reported to inhibit
flavivirus replication at different stages of their replication cycle
[19,20,21,22], we asked whether or not SFV785 could exhibit
DENV anti-viral activity in human HuH-7 cells. SFV785 reduced
the titer of DENV produced in a dose-dependent manner
(Figure 3A). Ribavirin was used at a concentration of 40 mM for
DENV (IC50) in HuH-7 cells [23]. The observed anti-viral effect of
this compound was not due to cell toxicity as the maximum
concentration of SFV785 used in this study (10 mM) was below its
CC50 value (the compound concentration required to kill 50% of
cells), which is .100 mM in HuH-7 cells. We tested the effect of
SFV785 on YFV production and found that SFV785 treatment
led to even more potent inhibition of this flavivirus (Figure 3B).
DENV and YFV belong to different sero-groups within the
Flavivirus genus [2]. Taken together with Figure 2, these data
indicate that SFV785 has a broad-spectrum activity against
Flaviviridae. In addition, a preliminary in vivo toxicity data from
mice orally administered with SFV785 indicated no adverse effects
or loss in body weight 7 days post-administration (Figure S1),
suggesting a potential therapeutic use of this compound.
The in vitro kinase screens performed earlier had highlighted
NTRK1 as the kinase most inhibited by SFV785. Hence we asked if
silencing of endogenous NTRK1 would have any effect on DENV
propagation. NTRK1-specific siRNAs (TrkA-3 or TrkA-12; Table S1)
Figure 3. SFV785 inhibits DENV-2 and YFV propagation. (A) DENV anti-viral activity of SFV785. HuH-7 cells were infected with DENV and
treated with SFV785 (5 or 10 mM) or with ribavirin (40 mM). The culture media were collected 36 hrs post-infection (p.i) and measured for viral titer by
plaque assays. (B) HuH-7 cells were infected with YFV and treated with SFV785 (5 or 10 mM) or ribavirin (200 mM). The culture media were collected
12 hrs p.i and assessed by plaque assays for viral titer. The bars indicate the range of PFU/ml from three biological replicates. (C) Knockdown of
NTRK1, one of the targets of SFV785, inhibited DENV propagation. The culture media and cell lysates from DENV infected HuH-7 cells treated with
mock transfection, C2 or NTRK1 (TrkA-3) siRNAs, were collected 36 hrs p.i. and analysed for viral titer by plaque assays and Western blot analysis,
respectively. Cells treated with SFV785 (10 mM) and infected with DENV were used as a control. The bars indicate the range of PFU/ml from three
biological replicates, each in triplicates. Similar results were obtained when NTRK1 knockdown was performed using TrkA-12 siRNA.
doi:10.1371/journal.pone.0023246.g003
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DENV and treated with SFV785 (10 mM) were used to compare the
effects of the compound on DENV propagation (Figure 3C). The
NTRK1-depleted cells were infected with DENV, the supernatants
harvested at 36 hrs p.i., and subsequently titrated for infectious virus.
NTRK1 knockdown resulted in a significant inhibition of infectious
DENV production, validating NTRK1 as one of the in vivo targets of
SFV785. While these data do not address how NTRK1 is involved in
DENV propagation, and do not rule out yet to be identified kinases as
the critical targets of SFV785, they do suggest NTRK1 as the best
candidate target for the compound.
SFV785 does not affect the intracellular accumulation of
DENV gene products
In order to assess the step of the viral life cycle affected by SFV785,
we measured the viral protein and RNA levels. SFV785 did not
inhibit viral protein or viral RNA synthesis (Figure 4A and B). These
observations were reaffirmed using HuH-7 cells electroporated with
the DRep DENV luciferase replicon, and grown in media with or
without SFV785. Cells treated with ribavirin, a guanosine ribonu-
cleoside analogue, were used as a control for the inhibition of viral
transcription without affecting input RNA translation. SFV785 did
not inhibit viral translation or RNA synthesis of the DENV replicon,
with a luciferase activity profile similar to that of untreated cells
(Figure 4C). As expected, cells treated with ribavirin showed
inhibition of viral RNA replication but not translation. These data
suggested that SFV785 did not inhibit viral RNA synthesis or
translation, and indeed, intracellular accumulation of DENV gene
products was unaffected.
SFV785 dislocates the DENV envelope protein from the
replication complex
We assessed the sub-cellular localization of DENV gene products
by indirect immunofluorescence using antibodies to the viral Env
Figure 4. SFV785 did not inhibit DENV viral RNA synthesis or translation. HuH-7 cells were infected with DENV, and untreated or treated
with SFV785 (10 mM) or with ribavirin (40 mM). The levels of (A) DENV protein in the cellular lysates by Western blot analysis, and (B) DENV RNA by
real-time PCR, are shown. The bars indicate the range of DENV copy number, normalized to cellular actin, from three biological replicates, each in
triplicates. (C) Effect on SFV785 on the replication of the DENV replicon. HuH-7 cells electroporated with the DENV replicons were pooled and
aliquoted in media untreated or treated with SFV785 (10 mM) or ribavirin (40 mM). The cells were harvested at the indicated time points and the
lysates assessed for luciferase activity. The bars indicate the S.D. from 4 separate experiments.
doi:10.1371/journal.pone.0023246.g004
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cells the Env protein showed the expected reticulate distribution,
consistent with our earlier data [15]. In SFV785 treated cells,
however, Env protein displayed discrete enlarged vesicular
distribution at the periphery of the nucleus (Figure 5A). Unlike
the Env protein, the pattern of NS3 in SFV785-treated DENV-2-
infected cells was indistinguishable from that in the untreated
DENV-2-infected cells (Figure 5B), indicating that the distinct
punctuate distribution of Env was specific. We next determined the
distribution of the discrete vesicles of Env with respect to the
dsRNA. In untreated cells the large majority of Env signal
overlapped with dsRNA, which we interpreted as tight colocaliza-
tion of Env and dsRNA, a marker for the DENV replication
complex [5]. In SFV785 treated cells the pattern of Env distribution
was very different from the pattern observed for dsRNA and a large
portion of the Env signal did not overlap the dsRNA signal
(Figure 5C, arrows). This implies that SFV785 dislocated a
significant portion of Env away from the replication complex.
As the Env is one of three structural proteins of an infectious
DENV, it is possible that an altered distribution of this protein
may affect the production of infectious DENV. In order to
determine the sub-cellular localization of the Env protein in
SFV785-treated cells, we stained for cellular markers of the ER
(calnexin; CALN), the ER-Golgi intermediate compartment
(ERGIC), COPII vesicles (sec31) and the Golgi organelles (giantin;
GOLGB1) [5]. As with our earlier results, Env in untreated cells
showed a distribution profile consistent with a reticulate ER
distribution, as shown by the distribution of CALN. In contrast, in
SFV785 treated cells, Env was in enlarged vesicles, with the
majority of the Env protein found to co-localize with the ER
chaperone CALN (Figure 6A) and not with the other cellular
markers (Figure 6B–D). In addition, in both uninfected and
infected cells, SFV785-treatment altered the distribution profile
of the CALN, but not of the other markers. It is worth noting that
in this study, the level of CALN was observed to increase with
DENV infection, consistent with earlier reports of a bulk
up-regulation in its expression in infected and bystander cells
[24,25]. Taken together, the data suggest that SFV785 may
cause morphological changes to the distribution of the specific
compartments of the ER. These changes alter the sub-cellular
distribution of Env, but not of NS3, suggesting a block in virion
assembly.
SFV785 alters ER structure and results in the formation of
DENV viral particles with abnormal morphology
The presence of DENV Env protein within ER-derived vesicles
and the reduction of extracellular infectious virus, suggested that
the consequence of SFV785 treatment could be a failure to form
and/or release of infectious virus particles. In order to examine the
effect of SFV785 on DENV propagation in detail, we used
electron microscopy. HuH-7 cells were treated with 10 mM
SFV785, infected with DENV at an MOI of 1 and processed
for electron microscopy (EM). Enlarged vesicles (Vd) were
observed in SFV785 treated uninfected HuH-7 cells, but were
absent in untreated uninfected cells (Figure 7A and B). The close
proximity to the ER (arrows) suggested that these drug-induced
vesicles were derived from the ER. DENV-infected cells, whether
untreated (Figure 7C and E) or treated (Figure 7D and F),
contained virus-induced ER-derived convoluted membranes
(CM), tubules (T) and vesicles (Ve) that were characteristic of
flavivirus infection [5]. Stacks of enveloped virus with dense
nucleocapsid core (Vi, ,50 nm) were observed within the dilated
ER cisternae in DENV-infected cells (Figure 7C). In addition, viral
particles (D) that were devoid of the dense nucleocapsid core and
with diameters larger than the expected for DENV were found
within the ER cisternae, even in those containing stacks of virions
(white arrow). The presence of defective viral particles within the
cells was not surprising since the production of defective flaviviral
particles has been previously reported [26,27]. We observed a
significant amount of defective viral particles (,60 nm) in SFV785
treated DENV-infected cells, and these were in close proximity to
virus-induced membranous structures (Figure 7D and F). These
results suggested that SFV785 induced the formation of discrete
vesicles, likely of ER origin. When administered to DENV-infected
cells, SFV785 caused an abnormal morphological distortion of
these vesicles, which prevented the proper assembly of the
enveloped virus. The formation of these enlarged vesicles in EM
Figure 5. The distribution profile of the dengue viral Env, but
not the NS3, is altered in infected cells treated with SFV785,
and does not co-localize with the replication complex. HuH-7
cells were infected with DENV and were either untreated or treated with
SFV785 (10 mM) for 36 hrs. The distribution profiles of the DENV (A) Env
and (B) NS3 proteins were visualized by fluorescent microscopy.
(C) DENV Env (green) and dsRNA (red) were visualized by fluorescent
microscopy. Arrowheads indicate representative cells showing no co-
localization of the vescicular-distributed Env with the dsRNA, a
presumed marker for the DENV RNA replication. The nuclei in all
experiments were stained with DAPI (blue).
doi:10.1371/journal.pone.0023246.g005
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fluoresence studies above.
SFV785 does not affect the secretion of virus particles
In order to determine if the secretion of DENV was affected by
SFV785, the supernatants of treated DENV-infected cells were
harvested 36 hrs p.i., and the amounts of DENV infectious particles,
proteins and viral RNA determined by plaque, antigen-capture
ELISA and real-time PCR assays respectively. Consistent with our
previous results, treatment with SFV785 and ribavirin inhibited the
production of infectious virus (Figure 8A), with a concomitant
decrease in the level of viral DENV RNA in the culture superna-
tants (Figure 8B). As expected, the supernatants of ribavirin treated
cells contained lower levels of DENV proteins. In contrast, the
supernatantsofSFV785-treatedcellswerefound tohavehigherlevels
of viral Env proteins (1.8 fold) as compared to untreated cells
Figure 6. Intracellular DENV protein is located within the endoplasmic reticulum in SFV785-treated cells. The subcellular localization of
DENV Env (green) proteins in DENV-infected HuH-7 cells, untreated or treated with SFV785 (10 mM), was visualized by fluorescent microscopy, with
the nuclei stained with DAPI (blue). Antibodies used for the detection of cellular marker proteins are indicated in the respective panels (red). The
cellular markers used were (A) calnexin (CALN) for the endoplasmic reticulum (ER), (B) ERGIC for the ER-Golgi intermediate compartments, (C) SEC31
for the COPII vesicles, and (D) GOLGB1 for the Golgi.
doi:10.1371/journal.pone.0023246.g006
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suggested that DENV RNA synthesis, translation, and subsequent
viral particle secretion were not affected by SFV785. The higher
production of defective viral particles in the culture supernatants of
SFV785-treated versus untreated infected cells (Figure 8C) was
somewhat surprising. Nonetheless, similar observations have been
reported in cultures of JEV with a change in the capsid protein that
prevents proper virus assembly [28].
EM analyses (Figure 7) and the above data suggested that the
DENV particles produced in SFV785-treated cells lacked a
nucleocapsid. To examine this, cell culture supernatants from
SFV785 treated and DENV-2 infected 3610
7 HuH-7 cells were
concentrated by ultracentifugation and analysed for the presence
of capsid (C) and pre-membrane (prM) structural proteins. The
supernatants from DENV-infected, SFV785 treated cells were
observed to express ,50% less C proteins, when normalised to the
level of the prM (Figure 8D), suggesting the presence of DENV
viral particles lacking capsid. Hence the results suggested that
SFV785 inhibited DENV propagation by disrupting the proper
assembly of the nucleocapsid into virions.
Discussion
Protein phosphorylation by kinases is known to modulate signal
transduction pathways that promote cell survival [29,30] and
immune evasion [31,32] during DENV infection, and the
regulation of endocytosis of other viruses (10). There are currently
a limited number of kinase inhibitors that has been documented to
inhibit DENV or flavivirus propagation at different stages of their
replication cycle [19,20,21,22]. Here we describe the synthesis and
characterization of the anti-viral activity of a kinase inhibitor,
SFV785. Our findings support the action of SFV785 at the
assembly stage of infectious DENV within the ER.
The effect of SFV785 on virus assembly, and not viral RNA
synthesis or translation within the ER compartment, can be placed
in context by a recent study of the three-dimensional architecture
and assembly sites of DENV replication [5]. The study showed
that the processes of DENV RNA replication and translation
occur in virus-induced vesicles within the lumen of ER, which are
in close proximity to, but distinct from, ER compartments that are
involved in virus assembly. These assembled viruses traverse the
Figure 7. Ultrastructural analysis of DENV-infected or uninfected HuH-7 cells that were either untreated or treated with SFV785.
HuH-7 cells were mock-infected (A, B) or infected with DENV (C–F) at an MOI of 1, and either untreated (A, C, E) or treated with SFV785 (10 mM) (B, D,
F). Cells were fixed at the late cycle of infection, incubated with 4% paraformaldehyde-PBS solution, and processed and analyzed by electron
microscopy. CM, convoluted membranes; D, probable defective virus; ER, endoplasmic reticulum; M, mitochondria; N, nucleus; T, virus-induced
tubules; Vd, probable drug-induced vacuoles; Ve, virus-induced vesicles; Vi, stacked DENV particles.
doi:10.1371/journal.pone.0023246.g007
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they accumulate as densely packed stacks before being transported
into the secretory pathway [5]. Consistent with the above study,
we observed the accumulation of viral particles and stacked
enveloped viruses within the ER compartments in SFV785 treated
cells and no inhibition in their secretion despite perturbations of
the ER structure. The majority of the viral particles secreted,
however, lacked the nucleocapsid, resulting in a reduction of
infectious virus titers. It is interesting to note that while the cellular
localization of the Env proteins was disrupted in the presence of
SFV785, that of NS3 was not. DENV utilizes the viral RNA-
dependent RNA polymerase (NS5), in concert with the host and
other viral NS proteins (including NS3), to synthesize comple-
mentary negative-strand RNAs from the genomic RNA template,
which in turn serves as templates for the synthesis of new positive-
strand RNAs [2]. Currently it is not clear how the DENV RNA
genome is packaged within the ER-derived prM-Env vesicles after
RNA synthesis. Thus this unexpected dichotomy on the cellular
localization of Env and NS3 with SFV785 can be potentially be
useful in dissecting these steps in the DENV life cycle.
SFV785 was shown to be an inhibitor to the NTRK1 and
MAPKAPK5 kinases. Reports of the involvement of protein
phosphorylation in the assembly of flaviviruses have been limited.
In HCV, the phosphorylation of the NS5A protein is critical for its
interaction with the core protein for the production of infectious
virus particles in HuH-7 cells [33] and for viral RNA synthesis
[34]. Phosphorylation of the HCV NS2A by CK2 kinase is also
reported to be necessary for the maturation step that confers
infectivity on assembled particles, without affecting protein
processing or genome replication [35]. In Vero cells, the c-Src
tyrosine kinase is involved in the budding of the DENV
nucleocapsid into the ER lumen [19], while the c-Yes kinase is
required for the trafficking of the West Nile virus (WNV) through
the secretory pathway [36]. NTRK1 is a tyrosine kinase and is
closely involved in the diseases Hereditary Sensory and Autonomic
Neuropathy (HSAN) IV and V [37,38]. Reports on the involve-
ment of NTRK1in virus propagation is limited, with NTRK1
reported to be critical in maintaining the latency of herpes simplex
virus (HSV) in cells [39,40]. MAPKAPK5, a major stress-activated
kinase, activates the heat shock protein 27 [41], which has been
Figure 8. SFV785 induces the production of non-infectious virus lacking the nucleocapsid, without affecting viral secretion. HuH-7
cells were infected with DENV and either untreated or treated with SFV785 (10 mM) or with ribavirin (40 mM). The culture media were collected 36 hrs
p.i., and measured for (A) the titers of infectious DENV produced by plaque assay and (B) the supernatant viral RNA. The bars indicate the S.D. from at
least 3 separate experiments. (C) Comparison of the concomitant levels of DENV protein from the supernatants of treated cells in (A). The amount of
DENV proteins was quantified by antigen-capture ELISA and shown as a percentage of the DENV proteins in the control untreated (DENV)
supernatant. The bars indicate the range of DENV proteins from triplicates of 2 independent experiments. P values indicate significant difference by
1-way ANOVA and Tukey’s post-test. (D) Western blot analysis of the capsid (C) and pre-membrane (prM) structural proteins from ultracentifugation-
concentrated supernatants of HuH-7 cells that were uninfected (control) or infected with DENV-2 and treated with or without SFV785.
doi:10.1371/journal.pone.0023246.g008
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including HSV-1 [42], HCV as a NS5A interacting partner [43],
and influenza virus as one of the host proteins detected in the virus
particle [44]. It is formally possible that SFV785 inhibits other yet
to be identified proteins that act at multiple steps of the DENV
replication cycle, leading to improper assembly of infectious
DENV.
Our studies indicate that SFV785 impinges on the DENV life
cycle by exerting its effect on the ER network itself. The dynamics
of the ER network is maintained by a plethora of proteins
including reticulons and cytoskeletal proteins [45]. NTRK1 is
reported to be involved in signalling pathways that modulate
cellular or ER membrane dynamics at specific sites via the
reorganization of the cytoskeletal proteins [46,47,48]. The capsid
(C) of HCV, a basic protein that is responsible for genome
packaging, is reported to interact with the a- and b-tubulin for
efficient infection and to promote virus transport and/or assembly
in infected cells [49,50]. In HCV and DENV infected cells, the
accumulation of cytoplasmic viral C proteins on the surface of lipid
droplets, which are ER-derived organelles [51] , is thought to be
crucial for the formation of infectious viruses [52,53]. Hence
perturbations of assembly-associated ER compartments by
SFV785 may interfere with the recruitment of the nucleocapsid
with the structural proteins, thus reducing the production of
infectious viruses
SFV785 is a broad-spectrum Flaviviridae inhibitor and it is likely
that it targets a common pathway required for the replication of
these viruses. Our toxicity data indicated that SFV785 was well-
tolerated when fed to mice at a dose of 1 g/kg/day for 1 week.
Hence the current studies not only indicate the usefulness of
SFV785 as a tool for the biochemical characterization of critical
host–virus interactions, but also underscore the potential of the
compound as a chemical starting point for anti-DENV pharma-
cological agents.
Supporting Information
Figure S1 SFV785 did not affect the growth of mice. The
growth and body weight of ICR-mice were monitored pre- and
post-administration of SFV785 (1 g/kg/day) or vehicle alone at
day 0. No significant weight differences were detected in mice with
or without SFV785 administration. Error bars indicate the range
of weight (n=6).
(TIF)
Table S1 Sequences of primers and siRNAs used in the
study. Sense and antisense primers were denoted with suffixes ‘f’
and ‘r’ respectively. The primers were designed according to
sequences reported in Genbank accession numbers M29095
(DENV-2) and NM001101 (actin).
(PDF)
Table S2 Kinase profiling of the inhibitory effect of
SFV785. The inhibitory effect of SFV785 was tested on 295
kinases. Kinases which showed a reduction of more than 50% in
activity with 10 mM of SFV785 were shaded in grey. The HUGO
nomenclatures of TrkA (NTRK1) and PRAK (MAPKAPK5) are
within the parentheses.
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